StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $15.18 | $16.11 | +6.13% | 0.1M |
| 05-12 | $16.15 | $15.75 | -2.48% | 0.0M |
| 05-13 | $15.81 | $14.64 | -7.40% | 0.1M |
| 05-14 | $14.73 | $14.76 | +0.20% | 0.0M |
| 05-15 | $14.43 | $14.17 | -1.80% | 0.0M |
No sell-side coverage available for BDSX.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Fundamentals not available for BDSX.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Each factor shows BDSX's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q3 2026 (Est.) Expected 2026-08-05 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $26.48M | $25.55M | $88.50M | $59.74M | $37.98M |
Operating Income | Not available | $-6.20M | $-27.87M | $-25.91M | $-18.86M |
Net Income | Not available | $-7.79M | $-35.27M | $-31.29M | $-11.47M |
EPS (Diluted) | $-0.88 | $-0.81 | $-4.67 | $-4.24 | $-0.15 |
Total Assets | Not available | $94.64M | $87.48M | $88.72M | $87.74M |
Total Liabilities | Not available | $85.50M | $89.94M | $90.44M | $86.60M |
Cash & Equivalents | Not available | $25.57M | $18.99M | $16.60M | $20.73M |
Free Cash Flow OCF − CapEx | Not available | $-10.25M | $-23.53M | $-24.22M | $-15.29M |
Shares Outstanding | Not available | 10.11M | 8.25M | 7.95M | 146.58M |
Biodesix Inc is a diagnostic solutions company with a focus on lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources: providing diagnostic testing services associated with blood-based lung and COVID tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties, as well as the development and commercialization of companion diagnostics.